Fetal Exploitive Products
Click on buttons below to see consumer products that are connected with the chain of supply
and demand for aborted fetal cells.
You might be asking yourself, alright how did we get to the place where we are using aborted babies to make products that I probably have sitting in my bathroom, pantry and kitchen? I know right?!
HEK293 ( Human Embryonic Kidney 293rd experiment) , the Genesis of Gene Therapy:
A single experiment which began in 1973 was the genesis of what later became a multibillion dollar industry. A Canadian researcher named Frank Graham tried to understand why some adenoviruses caused cancer and others did not. Adenoviruses are described by the CDC as common viruses that cause a range of illness. They can cause cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhea, and pink eye (conjunctivitis). (1)
Immortalizing the HEK293 cell line:
What we have been told:
To do this research Frank had to have a sufficient number of cells to work with. His wife Silvia Bachetti, identified that "HEK293 cells didn't express telomerase. The telomerase enzyme prevents telomeres (the repetitive DNA at chromosome tips) from shortening with every cell division. “Without telomerase the telomeres get shorter and shorter with every division until eventually they reach a critical length and the cell dies.” (2) Somehow they were able to isolate the cells that expressed telomerase and replicate those for their immortal cell line. This quality allowed them to grow viruses for researching therapies and treatments. It also allowed them to make therapeutic copies of the gene, to counteract the effect of the original mutation or treat a disease, without replicating to cause disease themselves. This laid the foundation of gene therapy. (2)
My first question about what we have been told:
From what I can glean there are four immortalized human cell lines, one for leukemia- Jurkat cells, two for cancer: HeLa - cervical cancer, and A549- lung tumor, and the only other one is HEK293. Somehow they were able to figure out how to take an enzyme to this particular specimen and immortalize it, yet find they have not done this with other vaccine material and instead have had to replace a waning supply of "successful" vaccine material using newly aborted live babies. (ie Walvax, as an alternative to WI-38 and MRC-5 --see Vaccines at a glance.)
More of what we have been told:
The cell line was used in academic circles on a limited basis, however, when a teenager died in a clinical trial where HEK293 was used, its use in gene therapy was discontinued. That happened in 1999. (2) In that very same year was the genesis of the use of HEK293 for millions of global consumer products. HEK293 would have a new lease on life in taste and smell experiments, for cleaners, and cosmetics and perfumes and gums etc. (3)
Second question.
How did that work exactly? We found out that we should NOT use this material for medical research and testing because it is linked to death and yet that same year marks the genesis of a multibillion dollar industry where HEK293 is used on an unrestricted basis by global corporations bringing it into nearly every household on the planet. How did that happen, what did that look like when it was happening?
They told us something got all worked out:
Because of the death associated with HEK293 its use in medical research was mostly put on hold until 2010 when they found out how to address the issue.
Third question:
They may as well say , this here HEK293 had to stop being used for medical science, because it was linked to death but then in 2010 "ABRACADABRA".
Somehow around the time that MRNA was being tested for vaccines they decided to revisit HEK293. It looks a lot like how they explained how this, the only "un-diseased" human cell line was able to infinitely reproduce. By making it look like they explained it without really telling us anything. Again maybe an explanation about how they solved the problem of people dying when HEK293 was used would be a good thing.
Senomyx - Pioneering the Use of Gene Therapy for Consumer Products:
“We’ve put together big pharma’s tools to come up with our discovery engine for smell and taste,” says Senomyx CEO Paul Grayson. (3)
History
Senomyx was born in 1999 when Charles Zuker ( University of California) and Nicholas Ryba, (National Institutes of Health ) published their work on the sweet and bitter taste receptors --which opened the door for using gene science for enhancing flavors. Two other key researchers came in to help establish Senomyx - Roger Tsien (University of California) and Lubert Stryer ( Stanford Medical School). They issued public stock offering in 2004, and in 2005 obtained the highly coveted regulatory approval GRAS
(Generally Recognize as Safe ) for several key flavors. In 2018 they were purchased by Firmenich.
Taste- an example of using gene therapy for Coca Cola:
Back in the 1990's researchers at soda companies were trying to find a way to sweeten their soft drinks and reduce calories. There was a particular receptor that acted like a Venus fly trap and closed when it was active and enjoying the sweetness. If they could find an enhancement that would not close the receptor , so that it could receive the sweetness, yet somehow fool it into staying closed longer, they could sweeten the soda using half the calories. Looking for published research on the NIH website for this breakthrough science kept cola researchers up throughout the night. Senomyx had promising research and was courted by the Coca-Cola company. Using traditional methods of human taste testers would have taken too long. Senomyx used HEK293 to screen 10,000 different compounds daily to find a suitable candidate that would mimic this Venus fly trap action in the receptor. After this, taste panelists selected for the sensitivity of their palates, would swish 'n sip sample liquids and spit it into cups until there was consensus that they had found the right taste . This is basically how it works for the tastes they are asked to “discover” by customers. (4)
Smell:
The era of creating synthetic aromas started in 1991 with the isolation of olfactory receptor genes. When the article "Sniffing for Success , Senomyx Inc" was written in 2000, they had counted more than 1000 olfactory receptor genes in rats and mice and over 500 in humans and Senomyx has intellectual property covering many of these.(3). The benefit of gene therapy for smells is that there are no regulations. They analyze and code the pattern of receptors that activate against certain chemical compounds to get an overall map of what odors go with what receptors. Over time they collect a library of molecular fingerprints for odorants. As Lubert Stryer of Senomyx puts it “If you can mimic an activity pattern at the periphery you will get the same perception,” (3)
The giveaway--"receptor modulating technology"
Look for any of these words. What this means is that the receptors you were born with are being modulated. According to the Cambridge Dictionary, "Modulate" means to change something, such as an action or a process, to make it more suitable for its situation. There is a vital difference between modulating a recipe, or the ingredients in contrast to modulating your receptors. All of these flavor and fragrance companies are excited about the science of changing your tongue and your nose. In fact the pinnacle for their craft would be to fool our tongues into thinking human waste is savory or have our nose believe the smell of necrotizing flesh is a floral bouquet . I kid you not , this is what Bill and Melinda spend their free time on see article-- Bill Gates tests ‘poop perfume’ as he sniffs out another solution to the world’s sanitation problems - GeekWire
Global Partners
Senomyx signed agreements with the following global companies: Kraft (2000) Campbell's Soup (2001), Coca-Cola and Nestle (2002) . Senomyx was responsible for the discovery, development, and regulatory approval phases of product development; its partners were responsible for manufacturing, marketing, selling, and distributing the consumer products containing Senomyx flavor ingredients.(5) As of December 31, 2017 according to Senomyx's annual report the company had agreements with Pepsi Co, Ajinomoto Co., Inc., and Firmenich SA.
Response to Boycott Pressure
In 2011 and 2012 Children of God for Life applied boycott pressure to a number of Senomyx partners/customers.
As far as we know, Campbell’s Soup did respond to boycott pressure from Children of God for Life and cancelled their agreements with Senomyx. (6) Pepsi Co, Kraft and Cadbury all lied, misleading the public into believing they no longer carried on the business of using fetal material in developing their products.
Pepsi artfully misled people into believing they listened, when in reality they accounted for 47% of Senomyx revenues in 2017 and aside from continuing in a collaborative agreement they also continued to pay royalties for Sweetmyx (TM) S617. (7) In a 2012 letter to Children of God for Life, PepsiCo stated, “Senomyx does not use HEK cells or any other tissues or cell lines derived from human embryos or fetuses for research performed on behalf of PepsiCo.” (6) Senomyx is all about using HEK293 to modulate taste and olfactory receptors, it is what they do, they would never stop using fetal material.
Kraft and Cadbury opted to rebrand by renaming their companies under the umbrella of Mondelez (8) which has been identified as a major customer of Firmenich (formerly Senomyx) in the article: Swiss flavour firm gets taste for post-Covid health food boom - France 24. The new name came about in 2012, the year after they told Children of God for Life that they had cancelled all their contracts with Senomyx. (6) Like Pepsi, they lied.
Firmenich buys Senomyx
In 2018 Firmenich purchased Senomyx. Firmenich, founded 185 years ago, is a privately owned Swiss Company and the second largest company in the fragrance and flavor industry. Prior agreements with major global players helped finance the research and development for 233 issued and 35 pending US patents, 422 issued and 187 pending foreign patents covering various aspects of proprietary technology and trademarks. As of the date of this purchase the Senomyx business model had transitioned from exclusive arrangements with global companies to direct sales of proprietary flavors, ingredients and trademark brands that had already cleared the regulatory hurdle as well as proprietary fragrances . (9)
The problem at hand is that Firmenich is a privately owned Swiss company, and there is no way to obtain transparency or accountability. Swiss rules over the privacy of companies are the most stringent in the world. So the maxim here is “caveat emptor, let the buyer beware” If something smells or tastes funny , use that. If it has an oddly addictive quality , it was probably synthesized.
Other players in the synthetic taste industry identified in Senomyx 2017 annual report (p.31 ):
Cargill - (1865) Cargill, Inc. is a privately held American global food corporation one of the largest in the world
Nestle SA- (1866) a publicly owned Swiss multinational food and drink processing conglomerate. The largest food company in the world,
Givaudan SA- (1895) a publicly owned Swiss multinational company . The largest manufacturer of flavors, fragrances and active cosmetic ingredients.
International Flavors & Fragrances Inc.,- (1958) publicly owned largest shareholder is DuPont 44.6%
Unilever - (1929) British multinational consumer goods company headquartered in London. Closest competitor to Nestle.
Chromocell Corp - (2003) a life sciences company using breakthrough science and technologies for consumer products.
Nutrasweet (1985) - privately held "reimagined" company
Nutrinova - (1997) global manufacturer of food constituents, subsidiary of publicly owned Celanese
AXXAM- (2001) Privately owned, based in Italy leading provider of integrated discovery services across Life Sciences industries ...
Other Companies that have taste or olfactory receptor modulating patents:
Proctor & Gamble
List will be updated as time allows and as more research continues
1 Centers for Disease Control and Prevention-Adenoviruses :Adenovirus | CDC
2. Mary Ann Liebert, Inc., publishers : Human Gene Therapy. Apr 2020.485-487.http://doi.org/10.1089/hum.2020.29116.oxg
Published in Volume: 31 Issue 7-8: April 16, 2020
3. William A. Wells. Sniffing for success Senomyx, Inc. Chemistry & Biology 2000, 7:R172–R173 Innovations
4. Wendy Wolfson. The Tastemakers: Senomyx Targets Taste Receptors. Chemistry & Biology 16, November 25, 2009 p1123-1124
5.Senomyx, Inc | Encyclopedia.com
7. Senomyx Dec 31, 2017 Annual Report p.58 snmx20171231_10k.htm (sec.gov)
8. I know , I know this is breaking a cardinal rule,using Wikipedia but it was the most sensible explanation I could find.
Mondelez International -Wikipedia
9. Senomyx Dec 31, 2017 Annual Report p.11-15 snmx20171231_10k.htm (sec.gov)